Oxford Spin-Out Just Landed $300M to Rewrite Tough Drug Targets

·
Listen to this article~4 min
Oxford Spin-Out Just Landed $300M to Rewrite Tough Drug Targets

OMass Therapeutics, an Oxford spin-out, raises $300M to advance its lead drug candidate and tackle undruggable targets. Here's why investors are betting big on European biotech.

What if you could drug the "undruggable"? That's the question OMass Therapeutics has been chasing since 2016. And now, with a fresh $300 million (€275 million) Series C round, they're one step closer to answering it. The UK biotech, a spin-out from Professor Dame Carol Robinson's lab at the University of Oxford, announced an oversubscribed round co-led by Bain Capital Life Sciences, Forbion, and Novo Holdings. Existing investors like Syncona, Oxford Science Enterprises, GV, and Sanofi Ventures also jumped back in. Not a bad vote of confidence. ### Why This Round Matters OMass isn't your typical biotech. They're using native mass spectrometry to study drug targets in their natural environment—think of it as observing animals in the wild instead of a zoo. Their OdyssION platform combines next-gen mass spec, novel biochemistry, and custom chemistry to tackle proteins that have historically been tough to drug. "This financing comes at an exciting point in OMass' evolution," says CEO Ros Deegan. "We have demonstrated the ability of our team and approach to discover and deliver a pipeline of first- and best-in-class programmes." The money will push their lead candidate, OMS1620, through Phase 2 trials for congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing's syndrome. It's a potential best-in-class MC2 receptor antagonist designed to stay on target longer. ### The Bigger Picture: Europe's Biotech Momentum OMass' round is part of a wave of European therapeutics funding in 2026. Just look at these recent deals: - **Bionyra Pharma** (France) – $156 million for inflammatory diseases - **Breye Therapeutics** (Denmark) – $73.5 million for oral small-molecule pipeline - **STORM Therapeutics** (UK) – $51.7 million - **Microbiotica** (UK) – $45.7 million - **Mironid** (UK) – $43.4 million - **Alchemab Therapeutics** (UK) – $31.9 million - **Laigo Bio** (Netherlands) – $6 million Together, these rounds add up to roughly $408 million in new financing—and that's before OMass' $300 million. With OMass included, the total swells to over $708 million. That's serious money flowing into European biotech. ### What's Next for OMass? The company plans to use the proceeds to advance OMS1620 and its SLC15A4 inhibitor, which is poised to follow. "We are entering our next phase of growth with the resources to translate that progress into a portfolio of clinically differentiated medicines for patients," Deegan adds. Investors are clearly bullish. "OMass leverages an experienced team and a clear vision for building a leading therapeutics company," says Evan Greif, Principal at Bain Capital Life Sciences. "We see meaningful potential for OMS1620 to improve the treatment for patients with CAH." Max Klement, Partner at Novo Holdings, echoes that sentiment: "Each of these candidates has the potential to address substantial unmet patient needs." So what does this mean for the broader startup ecosystem? For one, it shows that deep tech and biotech can still attract mega-rounds even in a cautious market. And for European incorporation, it's a reminder that world-class innovation often springs from university labs—and investors are willing to bet big on it. As OMass moves into the clinic, all eyes will be on whether their platform can truly unlock targets that have stumped the industry for decades. If they pull it off, this $300 million might look like a bargain.

📌 Worth Reading Next